Data Updates in Lung Cancer at ASCO 2023

home / data-dialogue-with-the-oncology-brothers / data-updates-in-lung-cancer-at-asco-2023

The Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Charu Aggarwal, MD, MPH, to discuss recent lung cancer data updates from clinical trials presented at the 2023 ASCO Annual Meeting.

Experts on lung cancer

EP. 1: ADAURA: Overall Survival Analysis of Osimertinib in NSCLC

Rohit Gosain, MD;Rahul Gosain, MD;Charu Aggarwal, MD, MPH
July 7th 2023

Charu Aggarwal, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data updates from the ADAURA trial, an overall survival analysis of osimertinib in non–small cell lung cancer (NSCLC).

Experts on lung cancer

EP. 2: KEYNOTE-789: Chemotherapy With or Without Pembrolizumab for TKI-Resistant Nonsquamous NSCLC

Rohit Gosain, MD;Rahul Gosain, MD;Charu Aggarwal, MD, MPH
July 7th 2023

Following ASCO 2023, experts in oncology review recent data updates from KEYNOTE-789 on chemotherapy with or without pembrolizumab for TKI-resistant nonsquamous NSCLC.

Experts on lung cancer

EP. 3: KEYNOTE-671: Perioperative Use of Pembrolizumab in Early-Stage NSCLC

Rohit Gosain, MD;Rahul Gosain, MD;Charu Aggarwal, MD, MPH
July 7th 2023

A review of recently updated data from KEYNOTE-671, focused on perioperative use of pembrolizumab in early-stage non–small cell lung cancer.

Experts on lung cancer

EP. 4: Closing Thoughts on Recent Data in Non–Small Cell Lung Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Charu Aggarwal, MD, MPH
July 7th 2023

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key NSCLC data updates discussed following the 2023 ASCO Annual Meeting.